]>
IRCT20170728035349N1 IRCT 2020-08-19 Zanjan University of Medical Sciences Evaluation of the effect of Famotidine in esophageal and cardiac cancer Evaluation of the radioprotective effects of famotidine in reducing the hematologic complications of esophageal and cardiac cancers chemoradiation. 2020-09-22 anticipated 60 Complete https://irct.ir/trial/50147 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Block randomization; participants are assigned in study groups by block randomization method. The blocks sample size is 4; two persons in intervention and two persons in control group. Different possible blocks are randomly selected to achieve final sample size, Blinding description: Participant do not know the intervention they receive. 3 Condition 1: Esopageal Cancer. Condition 2: Cardia Cancer. Intervention 1: Intervention group: 30 patients, 28 days of famotidine with 28 sessions of radiotherapy. Intervention 2: Control group: 30 patients take placebo for 28 days concurrent with radiotherapy sessions. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information
public Zhaleh Karimimoghaddam
Zanjan University of Medical Sciences ,Valiasr Hospital, ِDepartment of Radiotherapy
Zanjan Iran (Islamic Republic of) 45156-13191 +98 24 3302 3754 zhkarimi@zums.ac.ir Zanjan University of Medical Sciences scientific Zhaleh Karimimoghaddam
Zanjan University of Medical Sciences Valiasr Hospital Department of Radiotherapy
Zanjan Iran (Islamic Republic of) 45156-13191 +98 24 3302 3754 zhkarimi@zums.ac.ir Zanjan University of Medical Sciences Iran (Islamic Republic of) All patients with non-metastatic esophageal cancer and non-metastatic cardiac cancer aged 30 to 75 years who are candidates for radiotherapy and do not receive PPIs and other H2-blocker antagonists. Aged 30 to 75 years old Being candidates for chemo radiotherapy Do not receive PPIs and other H2-blocker antagonists. 30 years 75 years Both Patients who die during the project. Patients who are unable to continue treatment due to the severity of treatment complications. Patients who are unable to continue treatment due to the severity of treatment complications. Need to use PPI family drugs during the treatment process C15 C16.0 Malignant neoplasm of esophagus Malignant neoplasm of cardia Prevention Placebo Intervention group: 30 patients, 28 days of famotidine with 28 sessions of radiotherapy Control group: 30 patients take placebo for 28 days concurrent with radiotherapy sessions Blood Complications Chemo Radiotherapy for esophageal and cardiac cancers. Timepoint: Acute blood complications of chemo radiation weekly during radiotherapy with weekly CBC diff check for 5 weeks. Method of measurement: CBC diff blood sample. Zanjan University of Medical Sciences Approved 2020-08-03 Ethics Committee of Zanjan University of Medical Sciences Radiotherapy Department, Valiasr Hospital, Sheikh Fazlollah Nouri Highway, Zanjan City Zanjan Zanjan Iran (Islamic Republic of)